Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Events

06 Jun 2016 - 09 Jun 2016
22 Jun 2016 - 24 Jun 2016
04 Jul 2016 - 06 Jul 2016

Human Cell Line Produces High-Quality RSV for Vaccine Production

By BiotechDaily International staff writers
Posted on 23 Mar 2014
Print article
Image: Electron micrograph reveals the morphologic traits of the respiratory syncytial virus (RSV). The virion is variable in shape, and size (average diameter of between 120–300 nm). RSV is the most common cause of bronchiolitis and pneumonia among infants and children under one year of age (Photo courtesy of the CDC - [US] Centers for Disease Control and Prevention).
Image: Electron micrograph reveals the morphologic traits of the respiratory syncytial virus (RSV). The virion is variable in shape, and size (average diameter of between 120–300 nm). RSV is the most common cause of bronchiolitis and pneumonia among infants and children under one year of age (Photo courtesy of the CDC - [US] Centers for Disease Control and Prevention).
Cooperation between German and American biotechnology companies may pave the way for development of a vaccine to prevent RSV (respiratory syncytial virus) respiratory infections, which have been estimated to cause nearly 7% of the deaths of infants that die during their first year of life.

The companies involved are CEVEC Pharmaceuticals (Cologne, Germany), a clinical stage pharmaceutical company focusing on the development of highly potent protein and vaccine expression systems based on human CAP cells and Paragon Bioservices Inc. (Baltimore, MD, USA), a leading American biopharmaceutical contract manufacturer.

CEVEC has developed a new and proprietary expression system for biopharmaceuticals offering significant advantages over existing production technologies. Their CAP cells are an immortalized cell line derived from primary human amniocytes that meet the highest ethical and regulatory standards. CEVEC´s CAP cells have proven highly efficient in the production of a broad range of otherwise difficult to express glycoproteins. These molecules are produced at high titers with authentic post-translational modifications in serum-free suspension culture. Their ability to generate human glycosylation patterns also makes CAP cells a valuable tool for vaccine production.

The CEVEC/Paragon project has succeeded in producing RSV in CAP cells that show a high-level of functional G-protein resulting in a very effective RSV vaccine with positive impact on attenuated-vaccine studies.

"Again CAP cells prove their enormous potential and significant advantages over many currently used production systems for vaccines," said Dr. Rainer Lichtenberger, COO of CEVEC. "Next to Cytomegalovirus, influenza, and others, this is another striking example that CAP cells can efficiently propagate disease relevant human viruses. We were very pleased to work with Paragon on this project and benefited from their experience in vaccine production. This collaboration was extremely pleasant and successful."

Marco Chacón, CEO of Paragon said, "This teamwork pays not only for CEVEC, but also for Paragon. With use of CAP cells we can offer our customers a unique production system to meet the challenges of their vaccine target. With this highly ambitious project we have again proven our expertise in this competitive business."

Related Links:

CEVEC Pharmaceuticals
Paragon Bioservices Inc.



Print article

Channels

Genomics/Proteomics

view channel
Image: Follicular helper T-cells (TFH cells, shown in blue) play a crucial role in the maturation of antibody-producing B-cells (shown in green). Activated B-cells give rise germinal centers (shown in red), where mature B-cells proliferate and produce highly specific antibodies against pathogens. Top left: normal germinal center in a mouse tonsil. All others: Germinal centers fail to form when the interaction between ICOS and TBK1 is interrupted (Photo courtesy of Dr. Kok-Fai Kong, La Jolla Institute for Allergy and Immunology).

Molecular Pathway Controlling High-affinity Antibody Production Identified

A molecular pathway has been identified that controls formation of follicular helper T-cells (TFH cells) germinal centers and production of high-affinity antibodies through interaction with the inducible... Read more

Biochemistry

view channel
Image: A space-filling model of the anticonvulsant drug carbamazepine (Photo courtesy of Wikimedia Commons).

Wastewater May Contaminate Crops with Potentially Dangerous Pharmaceuticals

Reclaimed wastewater used to irrigate crops is contaminated with pharmaceutical residues that can be detected in the urine of those who consumed such produce. Investigators at the Hebrew University... Read more

Lab Technologies

view channel

Huge Modifiable Biomedical Database to Be Available on the Wikidata Site

Genome researchers are exploiting the power of the open Internet community Wikipedia database to create a comprehensive resource for geneticists, molecular biologists, and other interested life scientists. While efficiency in generating scientific data improves almost daily, applying meaningful relationships between... Read more

Business

view channel

European Biotech Agreement to Promote Antigen-Drug Conjugation Technology

Two European biotech companies have joined forces to exploit and commercialize an innovative, site-specific ADC (antigen-drug conjugate) conjugation technology. ProBioGen (Berlin, Germany), a company specializing in the development and manufacture of complex glycoproteins and Eucodis Bioscience (Vienna, Austria), a... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.